^
    2d
    Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P3, N=320, Recruiting, Genfleet Therapeutics (Shanghai) Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    gemcitabine • paclitaxel • 5-fluorouracil • irinotecan • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur)
    3d
    ATTRACTION-6: A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) (clinicaltrials.gov)
    P3, N=626, Active, not recruiting, Ono Pharmaceutical Co., Ltd. | Trial primary completion date: May 2026 --> Oct 2025
    Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    4d
    Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study (clinicaltrials.gov)
    P2, N=92, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    capecitabine • Teysuno (gimeracil/oteracil/tegafur)
    6d
    SOS-1 Study: A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, National Cancer Centre, Singapore | Trial primary completion date: Mar 2026 --> Oct 2025
    Trial primary completion date
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Teysuno (gimeracil/oteracil/tegafur)
    10d
    A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (clinicaltrials.gov)
    P1, N=102, Completed, Genentech, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • RG6440
    18d
    Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up results from JCOG1704. (PubMed, Gastric Cancer)
    Preoperative DOS for gastric cancer with ELM yielded unprecedentedly favorable 3-year survival outcomes and was considered a provisional standard of care without a phase III trial within our JCOG community.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    cisplatin • docetaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    19d
    Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma (clinicaltrials.gov)
    P2, N=92, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    capecitabine • Teysuno (gimeracil/oteracil/tegafur)
    23d
    Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant in BRCA1 who underwent staged risk-reducing salpingo-oophorectomy and contralateral risk-reducing mastectomy. (PubMed, Front Oncol)
    As postoperative adjuvant therapy, she received four cycles of doxorubicin and cyclophosphamide during pregnancy, followed by four cycles of docetaxel after delivery, along with tamoxifen and tegafur-gimeracil-oteracil potassium. She underwent staged risk-reducing salpingo-oophorectomy and CRRM after surgery for left breast cancer. Even in pregnancy-associated breast cancer complicated by HBOC, management should be individualized with careful consideration of safety, and the timing of each intervention should be determined according to the specific clinical circumstances of each patient.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • Teysuno (gimeracil/oteracil/tegafur)
    24d
    SYSKY-2023-1262-02: Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=32, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Sep 2026 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    AiTan (rivoceranib) • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
    24d
    Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies (PubMed, Gan To Kagaku Ryoho)
    To address the parallel needs for high QOL and disease control, we developed an alternative therapeutic approach termed"Coexistence Therapy for Cancer,"employing the combination of a carbohydrate-restricted ketogenic diet, metformin, vitamin-D, eicosapentaenoic acid (EPA) and additional complementary therapies, with S-1 (tegafur/gimeracil/oteracil potassium) at doses low enough to avoid side effects. These findings suggest that this therapeutic strategy may serve as a complementary treatment option for patients who are unable to tolerate standard chemotherapy. Further accumulation of clinical cases is required to validate the effectiveness of this approach.
    Trial completion • Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    metformin • Teysuno (gimeracil/oteracil/tegafur)
    26d
    IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=90, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)
    26d
    HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer (clinicaltrials.gov)
    P2, N=48, Not yet recruiting, Shanghai Changzheng Hospital
    New P2 trial
    |
    docetaxel • capecitabine • oxaliplatin • Hetronifly (serplulimab) • Teysuno (gimeracil/oteracil/tegafur)